Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,604 public trials 547 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Completed

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT02101944

Conditions
Anemia, Blood Protein Disorders, Cardiovascular Diseases, +15 more
Locations
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
View Trial Details
Completed

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

NCT02697383

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Memorial Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
View Trial Details
Completed

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

NCT02728102

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of California, San Francisco San Francisco, California, United States
  • Emory University Atlanta, Georgia, United States
  • University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States
  • Beth Israel Deaconess Medical Center/Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 15 locations
View Trial Details
Completed

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

NCT03217812

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Beijing Chaoyang Hospital Beijing, China
  • Peking Union Medical College Hospital Beijing, China
  • Peking University First Hospital Beijing, China
  • Beijing Chaoyang Hospital Beijing, China
View all 44 locations
View Trial Details
Completed

A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

NCT00457782

Conditions
B-cell Non-Hodgkin's Lymphoma, Blood Protein Disorders, Bronchial Diseases, +31 more
Locations
  • St Bartholomew's Hospital London, United Kingdom
  • UCLH London, United Kingdom
  • Christie Hospital Manchester, United Kingdom
  • Nottingham University NHS Trust Nottingham, United Kingdom
View Trial Details

Related conditions